Not Yet RecruitingNot Applicable

Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer.

324 participantsStarted 2025-01-01

Plain-language summary

A multicenter, prospective, randomized, controlled clinical trial of multi-technology integration total mesorectal excision (MTI-TME) versus conventional total mesorectal excision (C-TME) for the treatment of middle and distal rectal cancer

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants must be aged 18 to 75.
✓. Histopathological examination of the preoperative biopsy confirms adenocarcinoma.
✓. Preoperative MRI shows the tumor\'s lower margin is below the umbilical ligament.
✓. High-resolution CT and MRI do not indicate suspicious distant metastasis.
✓. Participants\' general condition is acceptable, with an ASA score of ≤3 before surgery.
✓. Participants must sign an informed consent form.

Exclusion criteria

✕. Developing other malignant tumors within 5 years;
✕. Multiple primary colorectal tumors;
✕. Pregnant or lactating women;
✕. Patients with severe mental disorders;
✕. Severe intestinal diseases;
✕. Poor general condition and uncontrolled comorbidities;
✕. Ineligible for laparoscopic surgery;
✕. Participating in other clinical trials.

What they're measuring

anastomotic leakage rate

Timeframe: 1 year

Trial details

NCT IDNCT06613399

SponsorThe First Affiliated Hospital with Nanjing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-01

Contact for this trial

Yueming Sun, MD

86-025-68306026 sunyueming@njmu.edu.cn

View on ClinicalTrials.gov More Rectal Cancer trials